Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1906 in Idiopathic Pulmonary Fibrosis
CTR20230121Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1906 in idiopathic pulmonary fibrosis (IPF), sponsored by Hengrui Therapeutics. Started Jan 2023; status: completed.
02
Drugs
SHR-1906
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20230121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230121.